Another fianlimab fiasco for Regeneron
The company discontinues the Lag3 project in lung cancer.
AACR 2026 – Matisse pains a mixed picture for Innate
IPH5201 plus Imfinzi in perioperative NSCLC looks better than some but not other historical studies.
Gilead edges further away from Arcus
The disclosure comes as another of Arcus's TIGIT trials flops.
Akeso casts doubts on CD73 efforts
The company has ditched a trial of drebuxelimab plus ivonescimab.
ASCO-GU – Padcev and Keytruda impress again
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
Another solstice for CTLA-4
Solstice Oncology acquires porustobart from Harbour Biomed.
Pivotal Claudin18.2 candidates keep coming
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
Ellipses Pharma widens its orbit
The biotech licenses a China-developed anti-B7-H3 ADC.
